If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Form 8.3 - DPH LN

30 Oct 2023 15:00

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the โ€œCodeโ€)

1. KEY INFORMATION

(a) Full name of discloser:

ย 

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

ย 

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ย 

Dechra Pharmaceuticals Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

ย 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

ย 

27 October 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state โ€œN/Aโ€

ย 

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

ย 

1p ordinary

ย 

Interests

ย 

Short positions

ย 

Number

ย 

%

ย 

Number

ย 

%

(1) Relevant securities owned and/or controlled:

ย 

ย 

ย 

ย 

(2) Cash-settled derivatives:

ย 

1,230,788

ย 

1.08%

ย 

ย 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

ย 

ย 

ย 

ย 

TOTAL:

ย 

1,230,788

ย 

1.08%

ย 

ย 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directorsโ€™ and other employee options)

Class of relevant security in relation to which subscription right exists:

ย 

Details, including nature of the rights concerned and relevant percentages:

ย 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

ย 

Purchase/sale

ย 

Number of securities

ย 

Price per unit

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

ย 

(b) Cash-settled derivative transactions

Class of relevant security

ย 

Product description

e.g. CFD

ย 

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

ย 

Number of reference securities

ย 

Price per unit

1p ordinary

ย 

CFD

ย 

Reducing a long position

ย 

45,583

ย 

3780.18

1p ordinary

ย 

CFD

ย 

Reducing a long position

ย 

100,000

ย 

3770.00

ย 

ย 

ย 

ย 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

ย 

Product description e.g. call option

ย 

Writing, purchasing, selling, varying etc.

ย 

Number of securities to which option relates

ย 

Exercise price per unit

ย 

Type

e.g. American, European etc.

ย 

Expiry date

ย 

Option money paid/ received per unit

ย 

ย 

ย 

ย 

ย 

ย 

ย 

(ii) Exercise

Class of relevant security

ย 

Product description

e.g. call option

ย 

Exercising/ exercised against

ย 

Number of securities

ย 

Exercise price per unit

ย 

ย 

ย 

ย 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

ย 

Nature of dealing

e.g. subscription, conversion

ย 

Details

ย 

Price per unit (if applicable)

ย 

ย 

ย 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state โ€œnoneโ€

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state โ€œnoneโ€

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

ย 

No

Date of disclosure:

ย 

30 October 2023

Contact name:

ย 

Daniel Mclachlan

Telephone number:

ย 

+44 203 770 8617

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panelโ€™s Market Surveillance Unit is available for consultation in relation to the Codeโ€™s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panelโ€™s Market Surveillance Unit.

The Code can be viewed on the Panelโ€™s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231030840874/en/

Copyright Business Wire 2023

Date   Source Headline
15th Nov 20232:49 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Nov 20231:30 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
15th Nov 20231:11 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Nov 202311:55 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Nov 202311:49 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
15th Nov 202311:41 amRNSHolding(s) in Company
15th Nov 202310:41 amGNWForm 8.3 - Dechra Pharmaceuticals PLC
15th Nov 202310:39 amRNSForm 8.5 (EPT/RI)
15th Nov 202310:37 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:51 amRNSHolding(s) in Company
15th Nov 20239:21 amRNSForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
15th Nov 20239:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Nov 20239:19 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
15th Nov 20238:17 amRNSHolding(s) in Company
15th Nov 20238:16 amRNSHolding(s) in Company
15th Nov 20238:14 amRNSHolding(s) in Company
15th Nov 20237:34 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
14th Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
14th Nov 20233:14 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
14th Nov 20231:49 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
14th Nov 20231:26 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC
14th Nov 20231:23 pmRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
14th Nov 202311:11 amRNSForm 8.3 - Dechra Pharmaceuticals plc
14th Nov 202311:06 amRNS2023 Notice of the Annual General Meeting
14th Nov 202310:24 amRNSForm 8.5 (EPT/RI)-Replacement of Dechra
14th Nov 202310:23 amRNSForm 8.5 (EPT/RI)
14th Nov 202310:19 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 202310:18 amRNSForm 8.5 (EPT/RI)-Replacement of Dechra
14th Nov 202310:17 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20239:10 amRNSForm 8.5 (EPT/NON-RI) Dehra Pharmaceuticals Plc
14th Nov 20238:53 amRNSForm 8.3 - Dechra Pharmaceuticals plc
14th Nov 20238:30 amRNSHolding(s) in Company
14th Nov 20238:30 amRNSHolding(s) in Company
14th Nov 20238:30 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
13th Nov 20232:30 pmPRNForm 8.3 - Dechra Pharmaceuticals Plc
13th Nov 20232:04 pmRNSForm 8.5 (EPT/RI)- Replacement of Dechra
13th Nov 20231:52 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
13th Nov 20231:48 pmRNSForm 8.5 (EPT/RI)
13th Nov 202312:54 pmPRNForm 8.3 - Dechra Pharmaceuticals plc
13th Nov 202312:44 pmRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
13th Nov 202312:10 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
13th Nov 202311:15 amRNSForm 8.3 - Dechra Pharmaceuticals plc
13th Nov 202310:23 amRNSForm 8.3 - Dechra Pharmaceuticals plc
13th Nov 202310:12 amRNSForm 8.5 (EPT/RI)
13th Nov 202310:09 amRNSForm 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PL
13th Nov 20238:53 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
10th Nov 20234:36 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
10th Nov 20233:42 pmRNSHolding(s) in Company
10th Nov 20233:30 pmRNSForm 8.3 - DPH LN
10th Nov 20233:15 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.